Compare Mesoblast Limited (MESO) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Yum! Brands, Inc. — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Yum! Brands, Inc. trades at $147.13 (market cap $40.62B). The key difference: Yum! Brands, Inc. is far larger — about 18.7× Mesoblast Limited's market cap, and Yum! Brands, Inc. pays a 2.04% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | YUM | |
|---|---|---|
Market Cap | $2.17B | $40.62B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $168.16 |
52-Week Low | $12.88 | $138.21 |
Enterprise Value | $2.17B | $51.88B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
YUM trades at $147.44, down 0.32% amid bearish technical signals and negative news flow from a Taco Bell lettuce contamination outbreak. Fundamentally, the company shows revenue growth to $8.21B in 2025 with strong net income margins of 20.48%, though valuation ratios like P/E of 23.86 appear elevated. Recent earnings have been mixed with Q1 2026 beating expectations but Q4 2025 missing estimates.
The stock faces near-term headwinds from the food safety crisis but maintains analyst support with a $177 consensus target representing 20% upside. Long-term growth prospects remain intact with digital expansion and brand strength, though high debt levels and competitive pressures present ongoing risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
